Overview

Reprometabolic Syndrome Mediates Subfertility in Obesity

Status:
Recruiting
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
Obesity plays an adverse role at every stage of conception and pregnancy and mounting evidence implicates relative hypogonadotropic hypogonadism, and reduced menstrual cycle hormone secretion as likely contributors to the subfertility phenotype and possible contributors to complications of pregnancy and the developmental origin of adult diseases such as diabetes and cardiovascular disease. This study will be the first comprehensive investigation to tie together the patterns of hyperinsulinemia, hyperlipidemia and inflammation, characteristic of obesity and obesity-caused relative hypogonadotropic hypogonadotropism and its potential adverse reproductive outcomes. The investigators findings will be used to inform a subsequent clinical intervention to optimize reproductive outcomes for obese women and their offspring.
Phase:
N/A
Details
Lead Sponsor:
University of Colorado, Denver
Treatments:
Anticoagulants
Heparin
Insulin
Insulin, Globin Zinc
Soybean oil, phospholipid emulsion